 |
 |
 |
 |
 |
 |
 |
 |
RECENT NEWS
- April 9, 2013 - EyeGate's EGP-437 Matches the Standard-of-Care's Response Rate in
Phase III Study of Patients with Anterior Uveitis. - December 18, 2012 - EyeGate Enrolls Last Patient in Pivotal Phase III Uveitis Study
- November 8, 2012 - The EyeGate II Delivery System: Addressing an unmet need for improved drug delivery.
Caution: New drug limited by Federal law
to investigational use only. Not for sale.